AZTherapies, which is developing an inhaled cromolyn sodium/ibuprofen formulation, has named Jay Mohr as Chief Operating Officer, Chief Business Officer, and Head of Commercial Development. Mohr was most recently co-founder and Managing Director of Locust Walk Partners.
According to his LinkedIn page, Mohr has some experience with OINDPs, beginning at Schering-Plough in the 1990s, where he was lead marketer for the launch of Nasonex nasal spray, and later as Chief Business Officer at Zelos Therapeutics where he was responsible for in-licensing intranasal technology from Aegis Therapeutics.
In 2015, AZTherapies announced that it was beginning a Phase 3 trial of its ALZT-OP1 delivered via the company’s Azhaler DPI for the treatment of Alzheimer’s disease. The company’s website indicates that ALZT-OP1 is also in development for ischemic stroke, and the pipeline includes therapies for Parkinson’s disease and ALS.
Mohr commented, “It’s an exciting time to be joining AZTherapies. With increasing acceptance that new approaches to fight Alzheimer’s disease are needed, I believe the company’s late-stage program could be a real breakthrough for early stage patients. I also believe that focusing on neuroinflammation as a root cause of neurodegenerative diseases is an idea whose time has come and I look forward to helping the company execute on its commercial, business development, and portfolio management strategies.”
AZTherapies Founder, CEO, and Chairman David R. Elmaleh said, “We are fortunate to have someone with Jay’s talents joining our senior leadership team at this key inflection point, when we are evolving from a science and innovation-driven company to one focused on regulatory filings and commercialization. I believe his diverse leadership, entrepreneurial, and industry experience is an ideal match for us, bringing depth and breadth of expertise across all aspects of our business, including strategic planning, corporate partnerships, and product commercialization, and having created significant shareholder value to both emerging biotech and large pharma organizations.”
Read the AZTherapies press release.
